Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Eastern Cooperative Oncology Group
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Nanjing Leads Biolabs Co.,Ltd
The First Affiliated Hospital with Nanjing Medical University
Dana-Farber Cancer Institute
Hoffmann-La Roche
Emory University
Zhejiang Cancer Hospital
Gilead Sciences
Gilead Sciences
M.D. Anderson Cancer Center
Japan Breast Cancer Research Group
Virginia Commonwealth University
IFOM ETS - The AIRC Institute of Molecular Oncology
Merck Sharp & Dohme LLC
City of Hope Medical Center
Dana-Farber Cancer Institute
University of Chicago
University of California, San Francisco
Thomas Jefferson University
Thomas Jefferson University
City of Hope Medical Center
The First Affiliated Hospital of Bengbu Medical University
NYU Langone Health
Orinove, Inc.
Merck Sharp & Dohme LLC
Guangdong Provincial People's Hospital
Actuate Therapeutics Inc.
Fujian Cancer Hospital
Fudan University
Fudan University
Fondazione Michelangelo
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
Case Comprehensive Cancer Center
Rutgers, The State University of New Jersey
Infinity Pharmaceuticals, Inc.
OncoSec Medical Incorporated
Barbara Ann Karmanos Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Spanish Breast Cancer Research Group
Hoffmann-La Roche
Hunan Cancer Hospital